Expertise in
1
conditions

Mareike Tometten

Aachen, NW, DE 
Expertise in
1
conditions
Aachen, NW, DE 

Overview

Mareike Tometten practices practicing medicine in Aachen, Germany.

Ms. Tometten is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Dyskeratosis Congenita, Head and Neck Squamous Cell Carcinoma (HNSCC), B-Cell Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 20 peer reviewed articles and participating in 1 clinical trial.

Gender

Female

Locations

Aachen, NW, Germany
Other Locations
Koeln, NW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab
Study Phase: Phase 3

20 Total Publications

OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117).
OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117).
Journal: British journal of cancer
Published: December 17, 2025

Frequently Asked Questions about Mareike Tometten

Is Mareike Tometten a top-rated expert for Dyskeratosis Congenita?

MediFind is an objective health platform that identifies experts based on real-world data. Mareike Tometten is classified as an Distinguished expert for Dyskeratosis Congenita, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Mareike Tometten participate in research or clinical trials?

Yes. Mareike Tometten has published 20 articles and abstracts on conditions like Dyskeratosis Congenita. You can view a list of Mareike Tometten's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Tometten's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile